Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)
Sponsor: Merck Sharp & Dohme LLC
A PHASE3 clinical study on Non-Small-Cell Lung Carcinoma, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 14 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 9 earlier versions
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .